Skip to content
AwardedSpainGoodsDynamic purchasing system€278,138

Adjudicación del Contrato Específico del Medicamento AMIVANTAMAB 350 MG CONCENTRADO PARA SOLUCIÓN, AMIVANTAMAB 1600 MG SOLUCIÓN INYECTABLE Y AMIVANTAMAB 2240 MG SOLUCIÓN INYECTABLE, derivado del Sistema Dinámico de Adquisición del Suministro de Medicamentos Exclusivos, para el Consorci Sanitari de Terrassa

Published
Published 5 June 2026

Overview

The Consorci Sanitari de Terrassa has awarded a contract for the supply of Amivantamab in three formulations (350 mg concentrate for solution, 1600 mg injectable solution, and 2240 mg injectable solution) to JANSSEN-CILAG, S.A. for a value of €278,137.80. The contract was awarded on 29 May 2026 through the Dynamic Acquisition System for the supply of exclusive medicines managed by the Consorci de Salut i d'Atenció Social de Catalunya.

Key details

Country
Spain
Status
Awarded
Category
Goods
Estimated value
€278,138
Procedure
Selective
Contract type
Dynamic purchasing system
Published
5 June 2026
Classification (CPV)
Pharmaceutical productsVarious medicinal products

Award outcome

Awarded value
€278,138
Award date
29 May 2026
Contract period
29 May 2026 → 24 May 2027
Winner
  • JANSSEN-CILAG, S.A.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    5 June 2026

Contracting authority

  • Consorci Sanitari de Terrassa

    Procuring entity

    Terrassa, Spain

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Adjudicación del Contrato Específico del Medicamento AMIVANTAMAB 350 MG CONCENTRADO PARA SOLUCIÓN, AMIVANTAMAB 1600 MG SOLUCIÓN INYECTABLE Y AMIVANTAMAB 2240 MG SOLUCIÓN INYECTABLE, derivado del Sistema Dinámico de Adquisición del Suministro de Medicamentos Exclusivos, para el Consorci Sanitari de Terrassa — won by JANSSEN-CILAG, S.A. — Skim